Affiliation:
1. Ural State Medical University, Healthcare Ministry of Russia; LLC Medical Association New Hospital
Abstract
At present time, long-acting bronchodilators are the main class of drugs for basis therapy of chronic obstructive pulmonary disease (COPD). COPD is characterized not only by a decrease in pulmonary function parameters, but also by a decline in cardiac contractility. The article presents the results of studies of four approved fixed long-acting anticholinergic drugs/long-acting beta2-agonists in the Russian Federation, according their effect on the cardiovascular system. The safety of LAMA/ LABA was proved in terms of relation to the cardiovascular system, additionally the positive effect on the pumping function of the heart was shown in patients with COPD, which confirms the value of dual bronchodilators for COPD treatment.
Reference42 articles.
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2018. www.goldcopd.org/.
2. Avdeev SN, Aysanov ZR, Arkhipov VV, et al. National clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease: clinical decision support algorithm. Pulmonologiya, 2017, 1: 13-20.
3. Jones PW, Nadeau G, Small M, Adamek L. Metabolic and cardiovascular comorbidity in COPD patients classified using the GOLD 2011 assessment framework. Eur Resp J, 2012, 40: P988.
4. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA, 1994, 272: 1497–1505.
5. Heindl S, Lehnert M, Criee CP et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Resp Crit Care Med, 2001, 164: 597–601.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献